ESMO 2022 | The importance of patient selection in breast cancer trials

Erika Hamilton, MD, Sarah Cannon Research Institute, Nashville, TN, comments on learnings from various trials assessing SERDs in breast cancer. As some SERDs have failed to provide measurable efficacy in patients, patient selection is an important factor in determining the success of studies, especially when there is heterogeneity in patients who progress on aromatase and CDK4/6 inhibitors. Dr Hamilton additionally comments on antibody-drug conjugates (ADCs) potentially moving to earlier lines of therapy. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.